Notably, the plasma levels of IL-6, IL-1β, and TNFα from DSS colitis mice were significantly diminished in mice that received anti-Myl9/12 Ab treatment in comparison to those that received control Ab treatment (Figure 2F). Here, MYL9 is linked to colitis.